Home›Research›Compare›Dalargin vs N-Acetyl Selank
Peptide ComparisonDalargin vs N-Acetyl Selank
Both are Neuro & Cognitive peptides.
Dalargin
Leu-enkephalin-Arg
No providers listed yet
Dalargin has published research citations on file; N-Acetyl Selank does not yet — the main evidence gap between them.
Dalargin
Evidence
N-Acetyl Selank
Evidence
| Your goal | Better option |
|---|---|
| Has published research citations | Dalargin |
| More provider options (0 vs 4) | N-Acetyl Selank |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Dalargin
N-Acetyl Selank
N-Acetyl Selank
No citations on file.
About Dalargin
Binds delta and mu opioid receptors with peripheral preference due to limited CNS penetration. Reduces gastric acid secretion, promotes mucosal blood flow, and inhibits ulcer formation via prostaglandin-mediated pathways.
About N-Acetyl Selank
Tuftsin-derived heptapeptide with structural modifications that resist enzymatic degradation. Modulates GABA-A receptor complex, increases enkephalin levels in limbic system, and influences serotonin metabolism.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Dalargin
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
N-Acetyl Selank
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Where to source these peptides
Dalargin
Browse directory →
Providers offeringN-Acetyl Selank
4 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Neuro & Cognitive Comparisons
Browse all peptides →Educational research tools — not medical advice.